Injectable semaglutide has been tested in large human trials, and approved medicines exist for specific conditions. The evidence is strong for those defined uses, but different products, doses and indications should not be treated as equivalent.
Still uncertain: Unverified compounded or research-market material should not be assumed equivalent to an authorised semaglutide medicine.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
STUDY DATA VISUAL
STEP 1 study snapshot: mean body-weight change
Adults with obesity/overweight without diabetes · N=1,961 · 68 weeks · primary estimand regardless of treatment discontinuation or rescue intervention · mean percentage body-weight change from baseline
This chart summarises one randomized trial population. It does not mean every semaglutide product or indication has the same evidence. Bars use a common 0–25% weight-change scale across these WhichPeps charts. Separate trials are not head-to-head comparisons; populations, estimands and designs can differ.
View chart values as text
STEP 1 study snapshot: mean body-weight change table
Group
Mean body-weight change
Placebo
−2.4%
Semaglutide
−14.9%
STEP 1 study snapshot: mean body-weight change table
Extensive Phase III evidence supports weight loss with regulated semaglutide. SELECT demonstrated cardiovascular benefit in a defined population, and STEP 9 showed improved knee-OA pain/function in adults with obesity.
Regulatory status
Wegovy (semaglutide) is authorised in the EU for weight management in defined adults and adolescents; authorisation and dosing are product-, route-, indication- and jurisdiction-specific.
Main limitations
An approved semaglutide active ingredient does not make unverified compounded/research-market material equivalent to an authorised product.
Safety
GI effects are common; authorised product information should govern contraindications, interactions, pregnancy advice and monitoring.
Evidence reviewed
2026-09-18
i
Extensive Phase III evidence supports weight loss with regulated semaglutide. SELECT demonstrated cardiovascular benefit in a defined population, and STEP 9 showed improved knee-OA pain/function in adults with obesity.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
GI effects are common; authorised product information should govern contraindications, interactions, pregnancy advice and monitoring.
Gastrointestinal adverse effects are common. Product information includes important warnings, contraindications and monitoring considerations; risks depend on indication, formulation and co-medication.
Technical details
Mechanism / biologyGLP-1 receptor agonism reduces appetite and energy intake, slows gastric emptying and improves glucose-dependent insulin secretion.
Route / formulation boundaryEvidence for licensed pre-filled injection pens cannot establish identity, concentration, sterility or equivalence of unverified semaglutide vials or non-authorised products.
Identity / data-quality noteSeparate injectable weight-management evidence from oral formulations and from semaglutide products authorised for other indications.
Study / label regimen evidenceApproved dosing plus large human trial evidence. Licensed injection dosing is titrated and product-specific; STEP 1 used 2.4 mg once weekly after escalation. See dosing records.
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
3structured study records
3outcome records
6linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
